John Overdeck’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.43M | Sell |
558,409
-1,305,785
| -70% | -$22.8M | 0.01% | 1652 |
|
|
2026
Q1 | $35.7M | Buy |
1,864,194
+662,667
| +55% | +$14.4M | 0.03% | 645 |
|
|
2025
Q4 | $26.4M | Buy |
1,201,527
+84,325
| +8% | +$1.52M | 0.04% | 590 |
|
|
2025
Q3 | $13.6M | Sell |
1,117,202
-115,525
| -9% | -$1.56M | 0.02% | 803 |
|
|
2025
Q2 | $23M | Buy |
1,232,727
+591,285
| +92% | +$11.7M | 0.04% | 501 |
|
|
2025
Q1 | $12.3M | Sell |
641,442
-219,746
| -26% | -$6.43M | 0.03% | 688 |
|
|
2024
Q4 | $31M | Buy |
861,188
+36,475
| +4% | +$1.23M | 0.07% | 354 |
|
|
2024
Q3 | $35M | Sell |
824,713
-310,467
| -27% | -$13.2M | 0.08% | 322 |
|
|
2024
Q2 | $45.7M | Buy |
1,135,180
+113,187
| +11% | +$4.72M | 0.1% | 227 |
|
|
2024
Q1 | $36.2M | Buy |
1,021,993
+320,639
| +46% | +$8.59M | 0.08% | 287 |
|
|
2023
Q4 | $20.7M | Sell |
701,354
-79,180
| -10% | -$1.64M | 0.05% | 407 |
|
|
2023
Q3 | $16.2M | Sell |
780,534
-427,271
| -35% | -$11.7M | 0.04% | 445 |
|
|
2023
Q2 | $29.6M | Buy |
1,207,805
+285,322
| +31% | +$9.18M | 0.07% | 312 |
|
|
2023
Q1 | $37.5M | Buy |
922,483
+42,778
| +5% | +$1.77M | 0.11% | 234 |
|
|
2022
Q4 | $39.5M | Buy |
879,705
+214,923
| +32% | +$9.73M | 0.12% | 197 |
|
|
2022
Q3 | $31.8M | Buy |
664,782
+140,533
| +27% | +$7.7M | 0.11% | 236 |
|
|
2022
Q2 | $31M | Buy |
524,249
+485,667
| +1,259% | +$39.9M | 0.1% | 237 |
|
|
2022
Q1 | $4.49M | Buy |
+38,582
| New | +$4.5M | 0.01% | 972 |
|
|
2021
Q3 | – | Sell |
-166,041
| Closed | -$18.3M | – | 4708 |
|
|
2021
Q2 | $16.2M | Sell |
166,041
-228,595
| -58% | -$20.4M | 0.04% | 580 |
|
|
2021
Q1 | $34.8M | Buy |
+394,636
| New | +$36.7M | 0.09% | 253 |
|
|
2020
Q4 | – | Sell |
-226,360
| Closed | -$23.3M | – | 3764 |
|
|
2020
Q3 | $25.7M | Buy |
226,360
+175,181
| +342% | +$18.4M | 0.09% | 237 |
|
|
2020
Q2 | $5.06M | Buy |
51,179
+36,106
| +240% | +$2.88M | 0.03% | 641 |
|
|
2020
Q1 | $970K | Buy |
+15,073
| New | +$1.06M | 0.01% | 1429 |
|
|
2019
Q4 | – | Sell |
-31,399
| Closed | -$1.94M | – | 3986 |
|
|
2019
Q3 | $1.85M | Sell |
31,399
-57,773
| -65% | -$3.69M | 0.01% | 1505 |
|
|
2019
Q2 | $5.75M | Sell |
89,172
-803,691
| -90% | -$51.9M | 0.02% | 830 |
|
|
2019
Q1 | $56.7M | Buy |
892,863
+251,487
| +39% | +$13.2M | 0.18% | 141 |
|
|
2018
Q4 | $24.4M | Sell |
641,376
-384,712
| -37% | -$13.6M | 0.1% | 279 |
|
|
2018
Q3 | $44M | Buy |
1,026,088
+964,302
| +1,561% | +$33.7M | 0.12% | 242 |
|
|
2018
Q2 | $1.36M | Buy |
+61,786
| New | +$760K | ﹤0.01% | 1905 |
|
|
2014
Q2 | – | Sell |
-1,110
| Closed | -$246K | – | 2351 |
|
|
2014
Q1 | $246K | Buy |
+1,110
| New | +$283K | ﹤0.01% | 1754 |
|
Other funds holding TNDM
SC
FLAM
GKIM
PIM
John Overdeck's TNDM Position: Q2 2026 in Review
John Overdeck reduced its Tandem Diabetes Care (TNDM) stake by 70% in Q2 2026, selling an estimated $22.8M and leaving 558,409 shares worth $8.43M. The position accounts for 0.01% of the portfolio, ranked #1652.
John Overdeck first reported a position in TNDM in Q1 2014 and has held it in 30 quarters since. The position peaked at $56.7M in Q1 2019. 272 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.
- John Overdeck held 558,409 shares of Tandem Diabetes Care worth $8.43M as of Q2 2026.
- John Overdeck sold 1,305,785 Tandem Diabetes Care shares in Q2 2026, an estimated $22.8M.
- Tandem Diabetes Care made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1652 holding.
- John Overdeck first reported a position in Tandem Diabetes Care in Q1 2014 and has held it in 30 quarters since.
- John Overdeck's Tandem Diabetes Care position peaked at $56.7M in Q1 2019.
- 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.